EE175 Cost-Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada
| Autor: | Fischer, A., Mac, S., Freiman, E., Marshall, J., Rand, K., Ramos-Goni, J.M. |
|---|---|
| Zdroj: | In Value in Health December 2023 26(12) Supplement:S84-S84 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect